Get started
DR.REDDYS LABORATORIES LTD.DR.REDDYS LABORATORIES LTD.DR.REDDYS LABORATORIES LTD.

DR.REDDYS LABORATORIES LTD.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

DRREDDY trade ideas

RDY: Top candidate to go long indian shares...$RDY has a very strong monthly trend that is currently active, and also a strong daily chart, showing a trend is now active. We can go long risking a fall under the red line on chart, if aggressive, following the daily signal but aiming to capture the monthly trend as well. This would be a huge reward to risk position if it were to pan out favorably for us. I see the $INRUSD chart as significantly strong, and similar to the period from 2016 to 2018, and $RDY has a good valuation here, as well as substantial growth potential going forward. Free cash flow yield is 7.93%, EPS growth is positive in the last quarter and in the last year, and they are not too indebted, the company certainly has good liquidity and sales are steadily albeit modetly growing. Best of luck, Ivan Labrie.
NYSE:RDYLong
by IvanLabrie
DRREDDY Outperforms Pharma Peers and ETFs In the dynamic world of pharmaceutical investments, DR. REDDY'S Laboratories (NSE: DRREDDY) (NYSE: RDY) stands out as a notable performer, surpassing Jazz Pharmaceuticals plc (JAZZ), Sarepta Therapeutics, Inc. (SRPT), and the iShares U.S. Pharmaceuticals (IHE) and SPDR S&P Pharmaceuticals (XPH) ETF’s, In terms of background, DR. REDDY'S Laboratories Ltd. (NSE: DRREDDY) (NYSE: RDY) is an Indian pharmaceutical company that specializes in both generic and proprietary pharmaceuticals. The company conducts research, development, manufacturing, and marketing of a wide spectrum of pharmaceutical products across various therapeutic areas. Dr. Reddy's has a global presence and is known for its innovation and contributions to the pharmaceutical industry, serving patients' healthcare needs worldwide. Over the course of the last three months DRREDDY share price increased 22% and RDY by 20%, which outpaces the performance witnessed in leading pharma ETFs like IHE (+8.9%) and XPH (+9.1%). Additionally DRREDDY’s share price increase overperformed the two leading pharma companies JAZZ (+12%) and SRPT (-2%) that are similarly valued. This analysis aims to unravel the key factors contributing to DRREDDYS' outperformance compared to the ETFs mentioned. Here are some of its fundamental metrics that seem to be working to distinguish DRREDDY’s from its sectoral peers Valuation Metrics: DRREDDYS' price-to-earnings (P/E) ratio, at 19.65, is relatively higher compared to the ETFs, indicating that investors have greater growth expectations for the company. Earnings Growth: DRREDDYS' robust earnings per share (EPS) of 283.95 is a testament to its profitability on a per-share basis, potentially driving its stock performance while compared to JAZZ’s -1.61 and SRPT’s ​​-10.41. Dividend Yield: DRREDDYS offers a forward dividend yield of 0.72%, lower than the ETFs (IHE: 1.91%, XPH: 1.29%) Risk: DRREDDYS maintains a beta of 0.32, indicating lower volatility compared to the ETFs (IHE: 0.56, XPH: 0.59) and the companies (JAZZ: 0.73, SRPT: 0.98) Dr. Reddy's Laboratories' exceptional performance can be attributed to its strategic initiatives. For example, the launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S. highlights its commitment to innovation and market expansion. Participation in sustainability initiatives like the FE-ECube Study aligns with global environmental trends. And also, its involvement in new therapies like CAR-T cell treatment reflects their approach towards healthcare innovation. These are only some examples of strategic moves that collectively contribute to strong financial performance compared to pharmaceutical ETFs (IHE and XPH) and companies (JAZZ) and (SRPT). The company’s financials presented on this analysis showcase a company with very bullish growth prospects. As Dr. REDDY’s continues to forge ahead with its strategic initiatives and dedication to their patients, it remains a compelling choice for investors seeking a strong performer in the pharmaceutical industry, poised for sustained growth and innovation.
NSE:DRREDDYLong
by jonah_garber
REDDYS LABS Dr. Reddy's Laboratories Ltd is a leading India-based pharamceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations. Stock is trading at 3.80 times its book value and maintaining a healthy dividend payout of 21.6% Zero pledging by promoters , Debt to Equity ratio of 0.17 Good Fundamentals , Stock formed Ascending triangle pattern in chart , breakout above 4465 will give good up move as mentioned
NSE:DRREDDYLong
by madhu2811
DRREDDY's is +25% YTD as Double-Digit Gains ContinueDr Reddy's Laboratories (NSE: DRREDDY)(NYSE: RDY) is a > MUN:10B pharma powerhouse based in India with a fast-expanding global footprint. This innovative juggernaut for pharma and biotech has witnessed a highly bullish price action uptrend YTD, with nearly 25% gains registered for its NSE ticker as of market close on Friday, situating share price some 5% above analyst forecasts. After the company released a comprehensive year-end report in recent weeks, it looks like solid fundamentals are underlying this impressive growth. Here are a couple core reasons why I think DRREDDY remains a strong investment opportunity over coming quarters: -In the past month Dr Reddy's has passed two US FDA inspections at three different plants in India. Particularly when looking at a pharma company, adherence to regulatory and quality standards is a make or break. The fact that Dr Reddy's is blazing through FDA inspections with zero observations is a strong sign that the company is upholding the global gold standard when it comes to regulatory/safety adherence, as well as giving a green light for the roll-out of new products. -Expansion into the global generics market will serve as an engine for growth moving forward. The company unveiled its foray into the generics business through the introduction of an innovative business unit called RGenX. Focusing on acute segment products, Dr. Reddy's aims to revolutionize the market by employing a unique model driven by channel partners, empowering retailers to distribute medicines without specific healthcare professional recommendations. This recent bold move, coupled with Dr. Reddy's consistent strides in penetrating the highly significant Indian market, positions the company exceptionally well to thrive amidst the soaring growth of the Indian pharmaceuticals market. Astute investors seeking promising ventures should take heed of this transformative development, as Dr. Reddy's emergence in the generics arena presents a lucrative opportunity for substantial rewards. -ESG values represent a core pillar of DRREDDY's business model, making this a rare investment opportunity in the pharma sector that you can feel good about. A look at the company's year end report evidences the length to which the company has committed itself to ambitious inclusivity and diversity goals by 2030 for its senior leadership, as well as a raft of initiatives intended to bolster environmental sustainability and community building. Above all, the company strives to reach over 1.5B people by 2030, which will represent >10% of the global population! As market segment increases, investors can expect portfolio gains to flow in as well, creating a win-win situation. Lastly, the company has been outperforming both market index baselines and is currently trading above its own MA ribbon. Notwithstanding a dip in share price caused by market jitters in May after missing EPS forecasts for FY Q4, share price has come roaring back, leaving analysts' forecasts in the dust. We're just beginning to witness the bullish potential of this pharma multibagger, if its not already on your watchlist or in your portfolio, I for one would take a second look.
NSE:DRREDDYLong
by BiotechBrandon